Why it happens
Wegovy quiets appetite, and intake often drops faster than the body expects. Less fuel plus an adjusting metabolism reads as fatigue, especially in transition weeks.
The four levers
Protein at every meal, visible water, a protected bedtime, and small regular meals instead of skipped ones. Most fatigue answers to those four before it answers to anything else.
The dose-cycle dip
Some people feel lower for a day or two after each weekly injection, then normal. Knowing the rhythm makes it manageable – schedule demanding days away from injection day if you notice a pattern.
Semaglutide acts on the GLP-1 receptor – the same signalling your gut uses after a meal.
When to call
Severe or worsening exhaustion, dizziness on standing, fainting, or fatigue with persistent vomiting deserve a same-day message to your clinician. See the 30-second film answers for this medication.
Why progress slows, and what a clinician looks at
Weight change is rarely linear, and a slowdown is the expected shape rather than a failure of the medication. Physiologically, energy requirements fall as body mass falls, so the same intake that once produced a deficit eventually does not. Appetite signalling also adapts. When someone reports a stall, a clinician generally reviews dose and where you are in the titration schedule, protein intake and resistance training as they relate to lean mass, sleep, alcohol, and other medications that affect weight independently. Some of those are adjustable and some are not. What a clinician will not do is promise that a dose increase resolves it. If lean mass is the concern, protecting muscle during treatment goes into what the evidence does and does not support.
How semaglutide works on the GLP-1 receptor
Semaglutide is a GLP-1 receptor agonist. GLP-1 is an incretin hormone your intestine releases after eating; it prompts insulin release when glucose is elevated, slows gastric emptying, and signals satiety in the hypothalamus. Semaglutide binds the same receptor, and structural modifications give it a long half-life, which is what makes once-weekly dosing possible for the injectable form. It acts on one receptor rather than two, which is the pharmacological difference from tirzepatide. According to the FDA prescribing information for semaglutide products, that mechanism is the basis of the approved indications. Oral semaglutide reaches the same receptor by a different route and carries strict dosing conditions as a result, which oral versus injectable semaglutide covers. Whether any form suits you is decided by a licensed clinician after an evaluation.
FDA has warned about dosing errors reported with compounded GLP-1 products.
What compounded means, and what it does not
A compounded preparation is made by a licensed pharmacy for an individual patient on receipt of a valid prescription. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. That is a statement about regulatory pathway, not an accusation about any particular pharmacy, and it is why the distinction matters more than marketing language does. A compounded preparation is not a generic and not an equivalent of any FDA-approved brand product. Published clinical trials such as STEP-1 studied the branded product at studied doses; those findings should not be assumed to transfer. What compounded means unpacks the legal framework, and red flags when buying online covers how to tell a legitimate pharmacy from a grey-market seller.
Why side effects are mostly digestive, and mostly early
Because the receptors semaglutide acts on sit in the gut and the brainstem, the predictable effects are digestive: nausea, reflux, constipation, diarrhoea, and a feeling of fullness that arrives sooner than expected. According to FDA prescribing information for semaglutide products, gastrointestinal reactions are the most commonly reported adverse events, and they are dose-related for many people. The practical implication is that they tend to cluster around a dose change rather than persist indefinitely. Serious risks are listed separately in the label, including pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumours in rodents. Those are not common, but they are the reason the medication is prescription-only. Report severe or persistent abdominal pain, vomiting that stops you keeping fluids down, or vision changes to your clinician promptly rather than waiting for a scheduled check-in.
Your intake goes to a licensed clinician, not an algorithm.
Frequently asked questions
How long does it last?
Usually most noticeable in the first weeks and after dose increases, fading as the body adjusts. Persistent fatigue merits an evaluation.
Tablets vs injection – same fatigue?
The driver is the appetite change and calorie drop, so it can occur with either form.
Could it be something else?
Yes – iron, thyroid, and sleep issues mimic it exactly, which is why fatigue that does not fade should be looked at properly.
How do I inject semaglutide?
Follow the instructions supplied with your specific preparation. Weekly peptide injections are generally subcutaneous, into the abdomen away from the navel, the outer thigh, or the back of the upper arm, rotating the site each week. Contact the pharmacy before injecting if anything about your dose or volume is unclear.
Where do you inject semaglutide?
Subcutaneous sites are the abdomen, outer thigh, and back of the upper arm. Rotating between them reduces local irritation. Your dispensing pharmacy provides site guidance for your preparation.
How long do semaglutide side effects last?
Gastrointestinal effects are dose-related for many people, so they commonly cluster around a dose change and settle as the body adapts. Persistent or severe symptoms are a reason to contact your clinician rather than wait.
Tired on Wegovy? Get it looked at properly
A licensed clinician reviews your history and decides what is appropriate. Rx only, refunded in full if you are not prescribed.
Rx only. A licensed clinician decides whether treatment is appropriate and may determine that no treatment, or a different treatment, is right for you. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Individual results vary.
Sources
Clinical trials listed below evaluated FDA-approved products at the doses studied. They are cited as published science, not as evidence about any compounded preparation, which is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality.
- FDAFDA prescribing information: Wegovy (adverse reactions)
- FDA databaseDrugs@FDA: search approved labeling for semaglutide
- Peer-reviewedSTEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM 2021)
- FDA guidanceFDA: Compounding and the FD&C Act, Section 503A
Spotted something inaccurate? Report an error – corrections are logged per our editorial standards.
More on Wegovy® Tablets
Same medication, different question.
